Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a recipient of a de novo kidney from a living or deceased donor~Exclusion Criteria:~* Subject has induction therapy, other than study-assigned basiliximab, planned as part of initial immunosuppressive regimen~* Subject has previously received or is receiving an organ transplant other than a kidney~* Subject will receive a solitary kidney from a deceased donor \< 5 years of age~* Subject will receive a kidney with an anticipated cold ischemia time (CIT) of \> 30 hours~* Subject will receive a kidney that meets both Extended Criteria Donor (ECD) and Donation after Cardiac Death (DCD) criteria. Note: a kidney that meets either ECD or DCD criteria is eligible for inclusion~* Subject will receive an ABO incompatible donor kidney~* Subject has a current calculated panel reactive antibody (cPRA) level \>50%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Basiliximab induction + Tacrolimus + MMF + Corticosteroids
- CNI avoidance (Type: EXPERIMENTAL): Basiliximab induction + ASKP1240 + MMF + Corticosteroids
- CNI minimization-MMF avoidance (Type: EXPERIMENTAL): Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).